ABVX – Abivax ADR

ABVX — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.99

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

0.45

EPS Last/This Y

2.14

EPS This/Next Y

0.39

Price

102.49

Target Price

146.27

Analyst Recom

1.39

Performance Q

-29.48

Upside

-284.8%

Beta

1.85

Ticker: ABVX

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ABVX	109.59	0.58	0.26	47125
2026-03-10	ABVX	115.27	0.58	0.29	48428
2026-03-11	ABVX	112.2	0.57	0.27	49501
2026-03-12	ABVX	116.99	0.57	0.17	50208
2026-03-13	ABVX	116.98	0.57	0.17	50208
2026-03-17	ABVX	126.66	0.55	0.38	55271
2026-03-18	ABVX	124.02	0.52	0.49	56359
2026-03-19	ABVX	122.99	0.52	0.35	57956
2026-03-20	ABVX	120.41	0.52	0.51	61006
2026-03-23	ABVX	115.02	0.45	0.93	52849
2026-03-24	ABVX	110.12	0.44	0.29	54945
2026-03-25	ABVX	110.64	0.43	0.36	60938
2026-03-26	ABVX	109.5	0.44	1.34	61731
2026-03-27	ABVX	102.47	0.47	0.85	64554
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

14 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ABVX	109.64	-	-	-4.42
2026-03-10	ABVX	115.15	-	-	-4.42
2026-03-11	ABVX	112.21	-	-	-4.42
2026-03-12	ABVX	116.94	-	-	-4.42
2026-03-13	ABVX	115.66	-	-	-4.42
2026-03-17	ABVX	126.68	-	-	-4.42
2026-03-18	ABVX	124.02	-	-	-4.42
2026-03-19	ABVX	122.90	-	-	-4.42
2026-03-20	ABVX	120.50	-	-	-4.42
2026-03-23	ABVX	115.05	-	-	-4.42
2026-03-24	ABVX	110.14	-	-	-4.42
2026-03-25	ABVX	110.66	-	-	-4.42
2026-03-26	ABVX	109.50	-	-	-4.42
2026-03-27	ABVX	102.49	-	-	-3.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

14 items 1 of 1

14 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ABVX	0.00	-1.74	4.78
2026-03-10	ABVX	0.00	-1.74	4.78
2026-03-11	ABVX	0.00	-1.74	4.93
2026-03-12	ABVX	0.00	-1.74	4.92
2026-03-13	ABVX	0.00	-1.74	4.92
2026-03-17	ABVX	0.00	-2.86	4.92
2026-03-18	ABVX	0.00	-2.86	4.92
2026-03-19	ABVX	0.00	-2.86	4.92
2026-03-20	ABVX	0.00	-2.86	4.92
2026-03-23	ABVX	0.00	-2.08	4.92
2026-03-24	ABVX	0.00	-2.08	4.92
2026-03-25	ABVX	0.00	-2.08	4.99
2026-03-26	ABVX	0.00	-2.08	4.99
2026-03-27	ABVX	0.00	-2.08	4.99
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

14 items 1 of 1

Last Quarter Act. EPS

-1.19

Avg. EPS Est. Current Quarter

-0.81

Avg. EPS Est. Next Quarter

-0.74

Insider Transactions

Institutional Transactions

-2.08

Beta

1.85

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.1

Max Drawdown 5-Year %

Target Price

146.27

P/E

Forward P/E

PEG

P/S

P/B

15.05

P/Free Cash Flow

EPS

-5.41

Average EPS Est. Cur. Y

-3.46

EPS Next Y. (Est.)

-3.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.42

Return on Equity vs Sector %

-101.2

Return on Equity vs Industry %

-84.9

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.18

EBIT Estimation

◆ ABVX Healthcare

$102.47

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

15/25

Volume

3/15

Valuation

10/20

TP/AR

2/10

Options

7/10

RSI

34.4

Range 1M

2.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

17/30

Estimates

0/20

Inst/Vol

3/15

Options

4/10

EPS Yr

31.2%

EPS NY

18.4%

52W%

68%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +42.7% upside

Quality

3/30

Valuation

10/30

Growth

13/25

Stability

7/10

LT Trend

1/5

Upside

+42.7%

Quality

Abivax SA

Sector: Healthcare

Industry: Biotechnology

Employees:

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABVX

Latest News

—

Caricamento notizie per ABVX…

stock quote shares ABVX – Abivax ADR Stock Price stock today

news today ABVX – Abivax ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ABVX – Abivax ADR yahoo finance google finance

stock history ABVX – Abivax ADR invest stock market

stock prices ABVX premarket after hours

ticker ABVX fair value insiders trading

SNY – Sanofi

SNY — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.31

Margin Of Safety %

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.22

EPS Last/This Y

1.23

EPS This/Next Y

0.32

Price

46.78

Target Price

56.9

Analyst Recom

1.71

Performance Q

-3.27

Upside

-33.6%

Beta

0.42

Ticker: SNY

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	SNY	48.66	1.03	1.47	56208
2026-03-03	SNY	46.5	1.00	0.49	57403
2026-03-04	SNY	46.24	0.99	0.32	58022
2026-03-06	SNY	44.52	0.98	0.30	59022
2026-03-09	SNY	44.38	0.97	1.43	59538
2026-03-10	SNY	44	0.98	1.33	61813
2026-03-11	SNY	43.97	0.97	3.66	61836
2026-03-12	SNY	43.65	0.98	0.29	62160
2026-03-13	SNY	43.63	0.98	0.43	62160
2026-03-17	SNY	44.09	0.96	0.06	61855
2026-03-18	SNY	43.72	0.94	1.87	62501
2026-03-20	SNY	44.64	0.92	2.62	62850
2026-03-25	SNY	46.06	1.12	0.06	50967
2026-03-26	SNY	46.62	1.07	0.33	52307
2026-03-27	SNY	46.8	1.03	0.69	53963
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	SNY	48.67	4.2	6199.7	5.00
2026-03-02	SNY	47.69	4.2	5455.8	5.01
2026-03-03	SNY	46.48	4.2	5448.5	5.01
2026-03-04	SNY	46.23	4.2	5621.1	5.01
2026-03-05	SNY	45.00	4.2	5392.8	5.01
2026-03-06	SNY	44.53	4.2	5588.7	5.01
2026-03-09	SNY	44.36	4.2	5596.8	5.01
2026-03-10	SNY	43.99	4.2	5576.4	5.01
2026-03-11	SNY	43.97	4.2	5343.3	5.01
2026-03-12	SNY	43.66	4.2	3784.6	5.01
2026-03-13	SNY	43.60	4.2	3733.7	5.01
2026-03-17	SNY	44.09	4.2	3851.1	5.01
2026-03-18	SNY	43.71	4.2	3694.4	5.01
2026-03-19	SNY	45.36	4.2	4191.6	5.01
2026-03-20	SNY	44.60	4.2	3489.5	5.01
2026-03-23	SNY	44.79	4.2	3584.3	5.01
2026-03-24	SNY	45.13	4.2	3791.6	5.01
2026-03-25	SNY	46.06	4.2	3876.2	5.01
2026-03-26	SNY	46.60	4.2	3835.5	5.01
2026-03-27	SNY	46.78	4.2	3733.3	5.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	SNY	0.00	-4.71	0.33
2026-03-02	SNY	0.00	-4.41	0.33
2026-03-03	SNY	0.00	-4.41	0.33
2026-03-04	SNY	0.00	-4.41	0.33
2026-03-05	SNY	0.00	-4.41	0.33
2026-03-06	SNY	0.00	-4.41	0.33
2026-03-09	SNY	0.00	0.46	0.33
2026-03-10	SNY	0.00	0.46	0.33
2026-03-11	SNY	0.00	0.46	0.27
2026-03-12	SNY	0.00	0.46	0.27
2026-03-13	SNY	0.00	0.46	0.27
2026-03-17	SNY	0.00	-0.31	0.27
2026-03-18	SNY	0.00	-0.31	0.27
2026-03-19	SNY	0.00	-0.31	0.27
2026-03-20	SNY	0.00	-0.31	0.27
2026-03-23	SNY	0.00	-0.08	0.27
2026-03-24	SNY	0.00	-0.08	0.27
2026-03-25	SNY	0.00	-0.08	0.31
2026-03-26	SNY	0.00	-0.08	0.31
2026-03-27	SNY	0.00	-0.08	0.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.89

Avg. EPS Est. Current Quarter

1.07

Avg. EPS Est. Next Quarter

1.11

Insider Transactions

Institutional Transactions

-0.08

Beta

0.42

Average Sales Estimate Current Quarter

10000

Average Sales Estimate Next Quarter

10745

Fair Value

59.55

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

22.2

Max Drawdown 5-Year %

-33.5

Target Price

56.9

P/E

19.59

Forward P/E

8.85

PEG

1.2

P/S

2.27

P/B

1.35

P/Free Cash Flow

10.71

EPS

2.39

Average EPS Est. Cur. Y

5.01

EPS Next Y. (Est.)

5.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

11.81

Relative Volume

0.89

Return on Equity vs Sector %

-21.9

Return on Equity vs Industry %

-31.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

3733.3

◆ SNY Healthcare

$46.78

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

10/25

Volume

7/15

Valuation

18/20

TP/AR

1/10

Options

2/10

RSI

58.4

Range 1M

76.8%

Sup Dist

1.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

10/30

Estimates

5/20

Inst/Vol

0/15

Options

5/10

EPS Yr

EPS NY

6.8%

52W%

28.8%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +36.6% upside

Quality

14/30

Valuation

15/30

Growth

8/25

Stability

4/10

LT Trend

1/5

Upside

+36.6%

Quality

MoS

27%

Sanofi

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 74846

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. Sanofi has a strategic collaboration with miRecule, Inc. to facilitate the advancement of therapy DUX4, a genetic driver of debilitating muscular disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

SNY

Latest News

—

Caricamento notizie per SNY…

stock quote shares SNY – Sanofi Stock Price stock today

news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025

marketwatch SNY – Sanofi yahoo finance google finance

stock history SNY – Sanofi invest stock market

stock prices SNY premarket after hours

ticker SNY fair value insiders trading

TTE – Total Energies SE

TTE — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.26

Margin Of Safety %

-27

Put/Call OI Ratio

0.68

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

-0.61

Price

89.82

Target Price

91.75

Analyst Recom

2.67

Performance Q

37.12

Upside

-15.2%

Beta

0.11

Ticker: TTE

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	TTE	80.29	0.77	0.86	77879
2026-03-03	TTE	78.39	0.77	0.67	78702
2026-03-04	TTE	76.9	0.77	1.33	79222
2026-03-06	TTE	78.72	0.77	0.04	79624
2026-03-09	TTE	80.47	0.75	0.46	81598
2026-03-10	TTE	80.08	0.75	0.90	82165
2026-03-11	TTE	81.33	0.75	1.58	82297
2026-03-12	TTE	81.64	0.75	0.53	82881
2026-03-13	TTE	81.42	0.75	0.44	82881
2026-03-17	TTE	86.01	0.75	0.07	83357
2026-03-18	TTE	86.9	0.72	0.69	85659
2026-03-20	TTE	88.69	0.68	0.18	91599
2026-03-25	TTE	89.29	0.69	0.31	76488
2026-03-26	TTE	89.95	0.68	0.26	77114
2026-03-27	TTE	89.8	0.68	0.54	78028
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	TTE	80.30	-	-586.5	6.67
2026-03-02	TTE	81.14	-	-4868.5	6.67
2026-03-03	TTE	78.39	-	-6369.1	6.67
2026-03-04	TTE	76.93	-	-6366.7	6.65
2026-03-05	TTE	77.12	-	-6006.4	6.65
2026-03-06	TTE	78.62	-	-5710.0	6.65
2026-03-09	TTE	80.31	-	-5552.2	6.68
2026-03-10	TTE	80.07	-	-5368.1	6.63
2026-03-11	TTE	81.33	-	-4989.4	6.63
2026-03-12	TTE	81.47	-	-5285.9	6.63
2026-03-13	TTE	82.73	-	-5144.8	6.63
2026-03-17	TTE	86.03	-	-4877.6	7.94
2026-03-18	TTE	86.94	-	-5143.1	7.94
2026-03-19	TTE	90.00	-	-4697.8	7.94
2026-03-20	TTE	88.69	-	-6364.2	7.94
2026-03-23	TTE	89.21	-	-5826.7	8.52
2026-03-24	TTE	88.79	-	-5665.1	8.52
2026-03-25	TTE	89.31	-	-5371.9	8.52
2026-03-26	TTE	90.00	-	-5140.3	8.52
2026-03-27	TTE	89.82	-	-5700.7	8.52
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	TTE	0.00	-15.30	0.26
2026-03-02	TTE	0.00	-15.32	0.26
2026-03-03	TTE	0.00	-15.32	0.26
2026-03-04	TTE	0.00	-15.32	0.26
2026-03-05	TTE	0.00	-15.32	0.26
2026-03-06	TTE	0.00	-15.32	0.26
2026-03-09	TTE	0.00	-15.11	0.26
2026-03-10	TTE	0.00	-15.11	0.26
2026-03-11	TTE	0.00	-15.11	0.21
2026-03-12	TTE	0.00	-15.11	0.21
2026-03-13	TTE	0.00	-15.11	0.21
2026-03-17	TTE	0.00	-15.19	0.21
2026-03-18	TTE	0.00	-15.19	0.21
2026-03-19	TTE	0.00	-15.19	0.21
2026-03-20	TTE	0.00	-15.19	0.21
2026-03-23	TTE	0.00	-15.22	0.21
2026-03-24	TTE	0.00	-15.22	0.21
2026-03-25	TTE	0.00	-15.22	0.26
2026-03-26	TTE	0.00	-15.22	0.26
2026-03-27	TTE	0.00	-15.22	0.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.92

Avg. EPS Est. Next Quarter

2.36

Insider Transactions

Institutional Transactions

-15.22

Beta

0.11

Average Sales Estimate Current Quarter

46598

Average Sales Estimate Next Quarter

50087

Fair Value

65.31

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.7

Max Drawdown 5-Year %

-26.3

Target Price

91.75

P/E

15.33

Forward P/E

10.67

PEG

1.19

P/S

1.05

P/B

1.68

P/Free Cash Flow

17.82

EPS

5.86

Average EPS Est. Cur. Y

8.52

EPS Next Y. (Est.)

7.91

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

7.2

Relative Volume

0.76

Return on Equity vs Sector %

1.6

Return on Equity vs Industry %

2.2

EPS 1 7Days Diff

1.9

EPS 1 30Days Diff

1.88

EBIT Estimation

-5700.7

◆ TTE Energy

$89.87

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

6/20

Pullback

8/25

Volume

9/15

Valuation

6/20

TP/AR

2/10

Options

5/10

RSI

76.5

Range 1M

89.9%

Sup Dist

0.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

9/25

Growth

5/30

Estimates

5/20

Inst/Vol

4/15

Options

6/10

EPS Yr

23.4%

EPS NY

-0.9%

52W%

96.1%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -0.6% upside

Quality

6/30

Valuation

3/30

Growth

7/25

Stability

3/10

LT Trend

4/5

Upside

-0.6%

Quality

MoS

-27%

TotalEnergies SE

Sector: Energy

Industry: Oil & Gas Integrated

Employees:

TotalEnergies SE, an integrated energy company, produces and markets oil and biofuels, natural gas, biogas and low-carbon hydrogen, renewables, and electricity in France, the United States, Europe, Brazil, India, and internationally. The company was formerly known as TOTAL SE and changed its name to TotalEnergies SE in June 2021. TotalEnergies SE was incorporated in 1924 and is headquartered in Courbevoie, France.

TTE

Latest News

—

Caricamento notizie per TTE…

stock quote shares TTE – Total Energies SE Stock Price stock today

news today TTE – Total Energies SE stock forecast ,stock prediction 2023 2024 2025

marketwatch TTE – Total Energies SE yahoo finance google finance

stock history TTE – Total Energies SE invest stock market

stock prices TTE premarket after hours

ticker TTE fair value insiders trading

CSTM – Constellium SE

CSTM — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

5.9

Margin Of Safety %

Put/Call OI Ratio

0.7

EPS Next Q Diff

-0.21

EPS Last/This Y

-0.23

EPS This/Next Y

0.16

Price

23.38

Target Price

Analyst Recom

Performance Q

23.65

Upside

189.0%

Beta

1.44

Ticker: CSTM

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	CSTM	24.87	0.92	1.24	24339
2026-03-02	CSTM	26.07	0.92	0.04	24398
2026-03-03	CSTM	25.84	0.90	0.39	24613
2026-03-04	CSTM	26.64	0.90	0.02	24671
2026-03-05	CSTM	26.37	0.90	0.71	24802
2026-03-06	CSTM	24.76	0.91	0.53	25243
2026-03-09	CSTM	25.18	0.90	0.34	25374
2026-03-10	CSTM	25.5	0.90	0.31	25440
2026-03-11	CSTM	25.32	0.89	0.06	25543
2026-03-12	CSTM	24.59	0.82	0.06	26849
2026-03-13	CSTM	24.59	0.82	0.09	26849
2026-03-17	CSTM	25.17	0.82	0.82	27279
2026-03-18	CSTM	24.68	0.82	0.67	27362
2026-03-19	CSTM	23.72	0.82	1.04	27391
2026-03-20	CSTM	22.39	0.84	2.50	27505
2026-03-23	CSTM	23.84	0.78	0.03	27547
2026-03-24	CSTM	24.65	0.71	0.08	29244
2026-03-25	CSTM	25.52	0.70	0.15	29476
2026-03-26	CSTM	23.95	0.70	0.67	29561
2026-03-27	CSTM	23.38	0.70	0.47	29602
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	CSTM	24.86	71.7	-	1.71
2026-03-02	CSTM	26.07	71.7	-	1.71
2026-03-03	CSTM	25.84	71.7	-	1.71
2026-03-04	CSTM	26.64	71.7	-	1.71
2026-03-05	CSTM	26.36	71.7	-	1.71
2026-03-06	CSTM	24.76	71.7	-	1.71
2026-03-09	CSTM	25.18	71.7	-	1.71
2026-03-10	CSTM	25.50	71.7	-	1.71
2026-03-11	CSTM	25.31	71.7	-	1.71
2026-03-12	CSTM	24.58	71.7	-	1.71
2026-03-13	CSTM	24.61	71.7	-	1.71
2026-03-17	CSTM	25.17	71.7	-	1.71
2026-03-18	CSTM	24.67	71.7	-	1.71
2026-03-19	CSTM	23.70	71.7	-	1.71
2026-03-20	CSTM	22.38	71.7	-	1.71
2026-03-23	CSTM	23.85	71.7	-	1.71
2026-03-24	CSTM	24.65	71.7	-	1.71
2026-03-25	CSTM	25.52	71.7	-	1.71
2026-03-26	CSTM	23.95	71.7	-	1.71
2026-03-27	CSTM	23.38	71.7	-	1.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	CSTM	-0.20	-7.41	3.92
2026-03-02	CSTM	-0.20	-2.80	4.00
2026-03-03	CSTM	-0.22	-2.80	4.00
2026-03-04	CSTM	-0.22	-2.80	4.00
2026-03-05	CSTM	-0.22	-2.80	4.00
2026-03-06	CSTM	-0.74	-2.80	4.00
2026-03-09	CSTM	-0.74	-2.63	4.00
2026-03-10	CSTM	-0.74	-2.63	4.00
2026-03-11	CSTM	-1.39	-2.63	5.95
2026-03-12	CSTM	-1.40	-2.63	5.95
2026-03-13	CSTM	-1.40	-2.63	5.95
2026-03-17	CSTM	-1.45	-2.72	5.95
2026-03-18	CSTM	-1.45	-2.72	5.95
2026-03-19	CSTM	-1.45	-2.72	5.95
2026-03-20	CSTM	-1.45	-2.72	5.95
2026-03-23	CSTM	-1.45	-2.72	5.95
2026-03-24	CSTM	-1.45	-2.72	5.95
2026-03-25	CSTM	-1.45	-2.72	5.90
2026-03-26	CSTM	-1.45	-2.72	5.90
2026-03-27	CSTM	-1.45	-2.72	5.90
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.68

Avg. EPS Est. Current Quarter

0.44

Avg. EPS Est. Next Quarter

0.47

Insider Transactions

-1.45

Institutional Transactions

-2.72

Beta

1.44

Average Sales Estimate Current Quarter

2042

Average Sales Estimate Next Quarter

2095

Fair Value

25.24

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.7

Max Drawdown 5-Year %

-66.3

Target Price

P/E

12.08

Forward P/E

9.99

PEG

P/S

0.37

P/B

3.32

P/Free Cash Flow

19.25

EPS

1.93

Average EPS Est. Cur. Y

1.72

EPS Next Y. (Est.)

1.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.23

Relative Volume

0.63

Return on Equity vs Sector %

13.4

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

◆ CSTM Basic Materials

$23.37

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

16/20

Pullback

15/25

Volume

6/15

Valuation

13/20

TP/AR

4/10

Options

3/10

RSI

44.4

Range 1M

24.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WATCH

Momentum

15/25

Growth

26/30

Estimates

9/20

Inst/Vol

4/15

Options

7/10

EPS Yr

62.7%

EPS NY

16.3%

52W%

79.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +98% upside

Quality

11/30

Valuation

19/30

Growth

20/25

Stability

2/10

LT Trend

0/5

Upside

+98%

Quality

MoS

Constellium SE

Sector: Basic Materials

Industry: Aluminum

Employees: 11500

Constellium SE, together with its subsidiaries, engages in the design, manufacture, and sale of rolled and extruded aluminum products for the aerospace, packaging, automotive, commercial transportation, general industrial, and defense end-markets. It operates through three segments: Packaging & Automotive Rolled Products, Aerospace & Transportation, and Automotive Structures & Industry. The Packaging & Automotive Rolled Products segment produces and develops rolled aluminum products, including canstock and closure stock for the beverage and food industry, as well as foil stock for the flexible packaging market. This segment also supplies automotive body sheets, heat exchangers, and battery foil products for the automotive market. The Aerospace & Transportation segment provides aluminum products including plate, sheet, and extrusions to aerospace, space, commercial transportation, general industrial, and defense sectors. The Automotive Structures & Industry segment offers structural solutions for the automotive industry including crash management systems, body structures, side impact beams, and battery enclosure components; soft and hard alloy extrusions for automotive, transportation, and general industrial applications; and profiles for rail and general industrial applications. This segment also provides downstream technology and services, which include pre-machining, surface treatment, research and development, and technical support services. It sells its products directly or through distributors in France, Germany, the Czech Republic, the United Kingdom, Switzerland, and the United States, as well as South Korea, Japan and China. The company was incorporated in 2010 and is headquartered in Paris, France.

CSTM

Latest News

—

Caricamento notizie per CSTM…

stock quote shares CSTM – Constellium SE Stock Price stock today

news today CSTM – Constellium SE stock forecast ,stock prediction 2023 2024 2025

marketwatch CSTM – Constellium SE yahoo finance google finance

stock history CSTM – Constellium SE invest stock market

stock prices CSTM premarket after hours

ticker CSTM fair value insiders trading

ABVX – Abivax ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ABVX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

SNY – Sanofi

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: SNY

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y